The FDA has approved Lipfendra, marking the first oral PCSK9 inhibitor for lowering LDL cholesterol. Clinical trials demonstrated that the drug can reduce LDL cholesterol levels by up to 60% over six months.
Priced at $10.50 per day, or $315 per month, Lipfendra offers a more affordable alternative to injectable treatments that cost between $500 and $600 monthly. Analysts project that the drug could reach peak annual sales exceeding $5 billion.
Merck plans to distribute Lipfendra through TrumpRx.gov, although a discounted pricing option has yet to be determined. This approval is significant for Merck as it seeks to diversify its revenue streams, particularly as competition for its cancer drug Keytruda is expected to increase.
The FDA expedited Lipfendra’s review under its National Priority Voucher program, reducing the timeline from several months to just a couple, underscoring the drug's potential impact on cholesterol management. Merck CEO Robert Davis expressed optimism about how the new treatment could change care in the U.S.
Currently, approximately 47 million adults in the U.S. could benefit from cholesterol medications but are not receiving them. The convenience of a daily pill may encourage more patients to seek treatment.
However, affordability remains a concern, with a recent poll indicating that 59% of Americans are anxious about rising prescription drug costs. Access and pricing will be critical for Lipfendra’s acceptance in the market.
This material is for informational purposes only and should not be considered financial advice.
